Contact hours available until 4/30/2021. Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation. Authors Conflict of Interest Disclosure: The author(s), editor, editorial board, content reviewers, and education director reported no actual or potential conflict of interest in relation to this continuing nursing education article. Commercial Support and Sponsorship: No commercial support or sponsorship declared. Accreditation Information: This educational activity is jointly provided by Anthony J. Jannetti, Inc. and the Academy of Medical-Surgical Nurses (AMSN).
Anthony J. Jannetti, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Anthony J. Jannetti, Inc. is a provider approved by the California Board of Registered Nursing, provider number CEP 5387. Licensees in the state of California must retain this certificate for four years after the CNE activity is completed.
This article was reviewed and formatted for contact hour credit by Michelle Boyd, MSN, RN, AMSN Education Director. Learning Outcome: After completing this learning activity, the learner will be able to discuss how patients with mild, moderate, or severe, persistent asthma benefit from daily treatment with a long-term controller medication, primarily inhaled corticosteroids (ICS). Learning Engagement Activity: List the four essential components of asthma management identified by the National Heart, Lung and Blood Institute - See Page 2 of the article. See Table 1 for additional information about daily doses of inhaled corticosteroids for adults.